Recurrent GBM Glioblastoma Multiforme - Healing Genes

Recurrent GBM Glioblastoma Multiforme

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy Combination With Radiotherapy and Chemotherapy for Recurrent Glioblastoma Multiforme

Phase 1 / 2


Houston Methodist Hospital is conducting a trial of an experimental treatment for recurrent glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) that involves using a virus to deliver a cancer suicide gene called HSV-tK to their tumor. In combination with valocyclovir medicine, this gene may cause the cancer to self-detonate by incorporating a molecule that stops their replication. This experimental treatment will be delivered along with standard radiation and chemotherapy.

The investigational treatment will be delivered during a surgery and be followed by radiation and chemotherapy, as determined appropriate by the managing physicians. Follow up with involve MRI or CT every 6 to 8 weeks after surgery, then every 12 to 14 weeks for 5 years.


  • Be 18 years of age or older
  • Have a diagnosis of glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA) confirmed by biopsy, which has not responded to prior standard treatment
  • Have a life expectancy ≥ 12 weeks
  • Be willing to use birth control, if sexually active


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Surgery to inject the viral genetic therapy.
  3. Within 24 hours valacyclovir will be given for 14 days.
  4. Within 9 days of surgery, radiation therapy will begin (30 visits over 6 weeks).
  5. Depending on the treating team’s judgement, the patient may also receive chemotherapy.
  6. Follow up with involve MRI or CT every 6 to 8 weeks after surgery, then every 12 to 14 weeks for 5 years.


The study sites are at the Houston Methodist Neurological Institute. Map.


David S. Baskin, MD  |  713-441-3803 or 713-201-5792  |  [email protected]

Helga M. Jones  |  713-363-9388  |  [email protected]


David Baskin MD

Center for Cell and Gene Therapy, Baylor College of Medicine

Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader